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Abstract
Background. Vascular calcifications and the bone frac-
tures caused by abnormal bone fragility, also called os-
teoporotic fractures, are frequent complications associated
with chronic kidney diseases (CKD). The aim of this study
was to investigate the association between vascular cal-
cifications, osteoporotic bone fractures and survival in
haemodialysis (HD) patients.
Methods. A total of 193 HD patients were followed up to
2 years. Vascular calcifications and osteoporotic vertebral
fractures(quotedjustasvertebral fracturesinthetext)were
assessed by thoracic, lumbar spine, pelvic and hand X-rays
andgradedaccordingtotheirseverity.Clinical,biochemical
and therapeutic data gathered during the total time spent on
HD were collected.
Results. The prevalence of aortic calcifications was higher
in HD patients than in a random-based general population
(79% versus 37.5%, P < 0.001). Total time on any renal
replacement therapy (RRT) and diabetes were positively
associated with a higher prevalence of vascular calcifica-
tions. In addition to these factors, time on HD was also
positively associated with the severity of vascular calci-
fications, and higher haemoglobin levels were associated
with a lower prevalence of severe vascular calcifications in
large and medium calibre arteries. The prevalence of ver-
tebral fractures in HD patients was similar to that of the
general population (26.5% versus 24.1%). Age and time on
HD showed a positive and statistically significant associ-
ation with the prevalence of vertebral fractures. Vascular
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calcifications in the medium calibre arteries were associ-
ated with a higher rate of prevalent vertebral fractures. In
women, severe vascular calcifications and vertebral frac-
tures were positively associated with mortality [RR = 3.2
(1.0–10.0) and RR = 4.8 (1.7–13.4), respectively].
Conclusions. Positive associations between vascular calci-
fications, vertebral fractures and mortality have been found
in patients on HD.
Keywords: haemodialysis; mortality; osteoporotic
fractures; vascular calcifications; vertebral fractures
Introduction
Vascular calcifications have been associated with adverse
clinical outcomes in CKD patients, including ischaemic
cardiacevents,claudicationandmortality[1–6].Thepatho-
genesis of vascular calcifications is complex and not fully
understood.Itdoesnotonlyconsistofasimpleprecipitation
of calcium (Ca) and phosphorus (P), but it is also an active
andmodifiableprocess.VascularcalcificationinCKDmay
be interpreted as a result of the dysregulation of the equi-
librium between calcification promoters and inhibitors in
which several uraemic factors, including abnormalities in
the mineral metabolism, are implicated [7–11]. Other risk
factorsforvascularcalcification,suchasage,diabetesmel-
litus, dyslipidaemia, hypertension and smoking, may play
a role not only in vascular calcification but also in bone
health.
Bonemineraldensityandosteoporoticfracturesarewell-
known markers of bone health in both general and CKD
populations [12,13]. However, until recently, they had not
been linked or associated with changes in the vascular sys-
tem. Experimental data have clearly shown that vascular
smooth muscle cells can modify their phenotype becoming
osteoblast-like cells able to induce vascular calcifications
[14–19]. This fact has opened a fascinating area of cross-
link research between vascular and mineral metabolisms.
In addition, recent data from general populations and CKD
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patientshaveshownthatnotonlyvascularcalcificationsbut
also osteoporotic fractures are associated with an increased
risk of mortality [20,21].
The aim of this multicentre study carried out in
haemodialysis (HD) patients was to investigate the associa-
tion between vascular calcifications, osteoporotic fractures
and survival in HD patients.
Material and methods
The study was carried out in 193 HD patients (121 men and
72 women) from a total of 258 patients from 7 HD units
in Asturias (Spain) followed up for 2 years.The clinical
practice protocols and the type of dialysis in all dialysis
unitsweresimilar,andthequalitycontrolofaluminium(Al)
in dialysis water in all units was performed in the reference
centre (Hospital Universitario Central de Asturias). Once
the informed consent was obtained, only the HD patients
who completed the radiological studies were subsequently
included in the study. Patients who did not give informed
consentandpatientswithseniledementiawerenotincluded
in the study. The mean age was 64 ± 14 years (men) and
68 ± 13 years (women); the mean time on HD was 3.1 ±
3.6 years. Most women (91.7%) were post-menopausal but
had never received oestrogen, selective oestrogen receptor
modulatorsorbisphosphonates.Vascularcalcificationsand
vertebral fractures were diagnosed following the methods
described below. Peripheral osteoporotic fractures reported
by patients were confirmed by medical records. Eighty-
four different parameters, including clinical, biochemical
and therapeutic information gathered during the total time
spent on HD, were collected. The arithmetic mean of the
monthlybiochemicalvaluessincethebeginningofHDuntil
the date of beginning of the study was obtained. Moreover,
the cumulative doses of Ca-, calcitriol- and Al-containing
phosphate binder received since the beginning of dialysis
were also investigated.
In order to diagnose vascular calcifications, all patients
underwentX-raystudies(thoracic,lumbarspine,pelvicand
hand). The analyses were done grouping the arteries into
threetypesaccordingtotheirsizeandthepredominantcon-
stituent of the tunica media: large or elastic arteries (aorta
and iliac) in which elastic fibres are the main component
of the media; medium (muscular or distributive) arteries
(femoral, uterine/spermatic and radial) in which smooth
muscle is the predominant constituent of the media and
small arteries (palmar arch and digital) in which also a
minor quantity of smooth muscle is present. Abdominal
aortic calcifications were graded according to their sever-
ity into mild (isolated punctiform calcifications), moderate
(linear calcifications with a maximum length of two ver-
tebral bodies or one dense plaque) and severe (linear cal-
cifications with a length of two or more vertebral bodies
and/or two or more dense plaques). Iliac, femoral, uter-
ine/spermatic, radial, palmar arch and digital vascular cal-
cificationswerealsogradedandgroupedasmild–moderate
when non-confluent calcifications or the partial section of
the vessel was calcified, and severe if contiguous calcifica-
tions involving multiple segments or the whole section of
the vessel were calcified.
Thoracic and lumbar spine X-rays were used to diagnose
vertebral fractures by a standard procedure detailed else-
where [22]. Vertebral fractures were classified according
to Genant’s semiquantitative method [23], which consid-
ers osteoporotic vertebral fractures as a reduction of the
vertebral height (anterior, posterior or middle) >20% after
excluding other causes of vertebral deformities.
Non-vertebral (peripheral) osteoporotic fractures were
included in the analysis only if they had been previously
confirmed in the medical records. Fractures were defined
as osteoporotic when they fulfilled the next two criteria:
(a) they were caused by a minor trauma or by a fall from
a maximum height equal to or below the upright position
of the patient and (b) localized in typical areas of osteo-
porotic fractures excluding skull, hands and feet. Vascular
calcificationsandvertebralfractureswereblindlyevaluated
by two independent experts with an inter-observer concor-
dance of 90% and a kappa index of 0.73 [20].
The HD patients were prospectively followed up for
2 years; patients contributed as person-time until they un-
derwent kidney transplantation, reached the end of the
follow-up period, died or were lost to follow-up.
The prevalences of aortic calcifications and vertebral
fractures were compared to a random-based general pop-
ulation cohort from the same geographic area (308 men
and 316 women; mean age 65 ± 9 years) who participated
in the European vertebral osteoporosis study (EVOS), in
which X-ray evaluations of thoracic and lumbar spine were
carried out following the aforementioned standard proce-
dure [22,24].
The clinical, biochemical and therapeutic data gathered
during the total time spent on HD were as follows:
• General and clinical data: gender, date of birth, pro-
fession, centre of dialysis, height, weight, dialysis
treatment, dairy product intake after starting dialysis,
physical activity, age of menarche, age of menopause,
number of births, breastfeeding, hysterectomy and pe-
ripheral and vertebral fractures.
• Renal disease and general HD data: aetiology of renal
disease(nephrosclerosisand/orischaemicrenaldisease,
diabetes,polycystickidneydisease,glomerulardisease,
tubulointersticial disease, other aetiology, unknown ae-
tiology), total time on dialysis, age of starting dialysis,
number of renal transplants, time on transplant, time on
replacement therapy (the sum of time on HD, time on
peritoneal dialysis and time on transplant), localization
of functioning arterious–venous fistula, time of each
HD session, bath solution use in a HD session (bicar-
bonate, Ca acetate), Kt/V and PCR.
• Risk factors and background: diabetes, time on dia-
betes, alcohol habits (actual hard-drinking, non-actual
hard-drinking, no hard-drinking), tobacco habits (cur-
rent smoker, non-smoker, former smoker), high blood
pressure, years of high blood pressure, bone diseases,
endocrinediseases,neurologicaldiseases,gastroentero-
logic diseases, respiratory diseases, cardiovascular dis-
eases, urologic diseases, parathyroidectomy and age of
parathyroidectomy.
• Biochemical data: serum Ca, P, Ca × P product,
parathyroid hormone (PTH), alkaline phosphatase, Al,Vascular calcification and fractures in haemodialysis 241
total cholesterol, HDL-cholesterol, triglycerides, total
proteins, albumin, haemoglobin, haematocrit and bi-
carbonate.
• Treatment: cumulative dose of Ca-, calcitriol- and Al-
containing compounds, corticosteroids, anticoagulants,
thyroid hormones, lipid-lowering drugs and insulin.
The study protocol was conducted according to the
Helsinki Declaration. Informed consent was obtained from
all the recruited patients and approved by the Clinical Re-
search Ethics Committee of Asturias. Statistical analyses
were performed with the SPSS version 8.0 software for
Windows. The prevalences of vascular calcifications and
vertebralfractureswereexpressedaspercentageswith95%
confidence intervals (CI). Differences in clinical and bio-
chemical data and the association between clinical and bio-
chemical variables and vascular calcifications were com-
paredusingt-testanalyses,multivariablelogisticregression
analyses and also non-parametric tests (Mann–Whitney U-
test)ifrequired.Thestrengthoftheassociationbetweenthe
prevalence of vascular calcifications and the prevalence of
vertebralfractureswascomparedbycalculatingtheORand
95%CIusingmultivariablelogisticregressionanalyses.All
these analyses were adjusted by age, time on dialysis, time
on RRT, haemoglobin, diabetes, sex and all treatments ad-
ministered.
Kaplan–Meier survival curves were used to examine
crude survival. Cox multiple regression analyses for cen-
sored survival data were performed to compare survival
between subjects with and without prevalent vertebral frac-
tures and vascular calcifications. The analyses were per-
formed separately for men and women after adjusting by
age and time on dialysis.
Results
The main clinical and biochemical data collected are sum-
marized in Table 1; there were no statistically significant
differences between the sexes.
Vascular calcifications, osteoporotic fractures and clinical
and biochemical parameters
Based on the calibre of the arteries, the prevalence of vas-
cular calcifications was 86.4% in large calibre, 70.5% in
medium calibre and 20.2% in small calibre arteries.
The prevalence of aortic calcifications was higher in HD
patients than in the general population (79% versus 37.5%,
P < 0.001). This difference was observed in both sexes
(77.8% versus 29.7% in women, P < 0.001 and 80.3%
versus 45.4% in men, P < 0.001). In HD patients, the
OR for having prevalent aortic calcifications (all grades)
compared with the general population was 8.7 (5.0–15.0).
In women, the OR was slightly higher than that in men
[OR = 9 (3.8–21) and OR = 7.7 (3.7–16.1), respectively].
Mean serum Ca, P, Ca × P, median iPTH and the me-
dian cumulative intake of calcitriol-, Ca- or Al-containing
phosphate binders, corticosteroids and other therapies were
not significantly associated with the prevalence of any type
of vascular calcifications (Table 2). From the rest of the
factors analysed, only age, time on HD, total time on any
RRT (HD, peritoneal dialysis or renal transplantation) and
diabetes were positively and significantly associated with a
higherprevalenceofvascularcalcifications(Table3).After
ageandsexadjustments,themultivariatelogisticregression
analysis showed that only time on RRT and diabetes main-
tained the positive association.
Age was associated with vascular calcifications in large
and medium calibre arteries while time on HD and total
time on RRT were associated with an increased risk of
vascularcalcification,onlyinmediumcalibrearteries,such
as femoral arteries [OR = 1.26 (1.07–1.48) and OR =
1.17 (1.04–1.32)], radial arteries [OR = 1.17 (1.02–1.33)
and OR = 1.13 (1.02–1.24)] and uterine/spermatic arteries
[OR = 1.20 (1.04–1.39) and OR = 1.15 (1.03–1.29)].
Diabetes was the most relevant variable associated with
an increased risk of vascular calcifications, mainly in small
and medium calibre arteries, such as digital [OR = 18.2
(4.7–70.2)], palmar arch [OR = 17.6 (4.8–65)], radial [OR
= 13.4 (3.8–47.7)], uterine/spermatic arteries [OR = 3.1
(1.1–9.1)] and femoral arteries [OR = 5.5 (1.6–18.5)], but
no association was found in large calibre arteries, iliac and
aorta arteries [OR = 0.4 (0.1–1.5) and OR = 1.1 (0.3–
3.9), respectively]. The other multiple clinical conditions
detailed before showed no association with vascular cal-
cifications at any site in the univariate and multivariate
analyses.
The prevalence of severe vascular calcifications was
63.6%and70.7%inlargecalibrearteries,55.6%inmedium
calibre arteries and 14.1% in small calibre arteries. The
severity of vascular calcifications in small calibre arteries
was significantly higher in men than in women (20.3% ver-
sus 5%, P < 0.05). There was no association between the
severity of vascular calcifications and biochemical param-
eters and the cumulative dose of drugs received.
Inlargeandmediumcalibrearteries,higherhaemoglobin
levels were associated with a lower prevalence of severe
vascular calcifications [OR = 0.74 (0.55–0.99) and OR =
0.65(0.44–0.96),respectively].Amongtheotherregistered
and analysed factors, time on RRT was positively and sig-
nificantly associated with the prevalence of severe vascular
calcifications in large and medium calibre arteries [OR =
1.23(1.03–1.47)andOR=1.18(1.02–1.36),respectively];
the time on HD was also positively and significantly asso-
ciated with the prevalence of severe vascular calcifications
in medium calibre arteries [OR = 1.47 (1.15–1.87)].
Similarly, diabetes was also positively associated with
the severity of vascular calcifications [OR = 6.43 (1.65–
25.11)]. This effect was more remarkable in small and
medium calibre arteries compared with large calibre arter-
ies [small calibre: OR = 83.17 (11.81–585.86), medium
calibre: OR = 33.38 (3.69–301.88) and large calibre:
OR = 2.07 (0.57–7.54)].
The prevalence of vertebral fractures in HD patients was
26.5%,slightlyhigherinwomenthaninmen(33.3%versus
21.7%, P = 0.162) and similar to the values found in the
general population, 24.1% (27.3% in women versus 20.7%
in men, P = 0.056) [25]. It was more common to have two
or more vertebral fractures in women than in men (25.5%
versus 6%, P < 0.05). Among all the different clinical and
biochemical parameters analysed, only age and time on HD242 M. Rodr´ ıguez-Garc´ ı et al.
Table 1. Clinical variables in HD patients by sex
Men (n = 121) Women (n = 72)
Age (years) 64 ± 14 68 ± 13
Time on RRT (years) 3.3 ± 4.2 3.9 ± 4.3
Time on HD (years) 2.7 ± 2.9 3.8 ± 4.5
Mean Ca (mg/dl) 9.4 ± 0.8 9.5 ± 0.7
Mean P (mg/dl) 5.4 ± 1.2 5.8 ± 1.3
Mean Ca × P (mg2/dl2)5 1 ± 13 53 ± 12
iPTH (pg/ml) 141(17–877) 203(8–1581)
Cumulative intake of Ca (kg) 1.1 (0.5–2.4) 0.9 (0.3–2.4)
Cumulative intake of calcitriol (mg) 46 (22–107) 59 (23–165)
Cumulative intake of Al(OH)3 (kg) 0.5 (0.3–2.5) 0.3 (0.1–1.5)
Diabetes mellitus (%) 23.1 19.4
Any treatment with corticoids (%) 23.1 23.6
Treatment with cholesterol-lowering drugs (%) 12.5 8.3
Previous renal transplant (%) 10.2 9.4
RRT, renal replacement therapy; HD, haemodialysis; PTH, parathyroid hormone.
No statistically significant differences were found according to gender.
iPTH and cumulative intake of Ca, calcitriol and Al were expressed as median and interquartile range.
In this case, the Mann–Whitney test was used for comparison.
Table 2. Meanandstandarddeviationvaluesofbiochemicalparameters(Ca,PandPTH),medianvaluesandinterquartilerangeofPTH,andcumulative
dose of calcitriol, Ca and Al in patients with (yes) or without (no) vascular calcifications in different arterial localizations
Calcifications in large calibre
arteries
Calcifications in medium
calibre arteries
Calcifications in small calibre
arteries
Yes No Yes No Yes No
Ca (mg/dl) 9.5 ± 0.7 9.4 ± 19 . 5 ± 0.8 9.4 ± 0.6 9.4 ± 0.7 9.5 ± 0.7
P (mg/dl) 5.4 ± 1.2 5.6 ± 1.3 5.3 ± 0.9 5.7 ± 1.4 5.6 ± 15 . 5 ± 1.3
Ca × P (mg2/dl2)5 0 ± 10 52 ± 14 50 ± 10 53 ± 12 51 ± 95 1 ± 11
iPTH (pg/ml) 141 (72–245) 269 (129–342) 143 (80–278) 147 (67–295) 138 (108–231) 143 (69–289)
Cumulative intake of calcitriol (mg) 50 (22–50) 77(23–98) 50 (24–160) 77 (19–95) 67 (21–179) 50 (22–107)
Cumulative intake of Ca-containing
phosphate binders (kg)
1.1 (0.5–2.9) 1.0 (0.3–2.4) 1.1 (0.5–3.1) 0.9 (0.3–2.3) 0.9 (0.4–3.2) 1.2 (0.4–2.8)
Cumulative intake of Al-containing
phosphate binders (kg)
0.5 (0.2–1.0) 0.4 (0.1–1.7) 0.5 (0.2–1.1) 0.4 (0.1–0.6) 0.4 (0.2–0.8) 1.1 (0.1–1.)
PTH, parathyroid hormone.
No statistically significant differences were found.
Table 3. Age, time on haemodialysis (HD), time on renal replacement therapy (RRT) in patients with (yes) or without (no) vascular calcifications at
different calibre arteries
Calcifications in large calibre
arteries
Calcifications in medium calibre
arteries
Calcifications in small calibre
arteries
Yes No P Yes No P Yes No P
Age 66 ± 14 51 ± 20 0.01∗ 66 ± 14 57 ± 19 0.019∗ 64 ± 13 64 ± 16.5 NS
Time on HD (years) 2.8 ± 32 . 2 ± 3.3 NS 3.2 ± 3.5 1.7 ± 1.1 0.001∗ 2.8 ± 3.1 2.9 ± 3.2 NS
Time on RRT (years) 3.5 ± 4.5 2.8 ± 4N S3 . 9 ± 4.9 2.2 ± 2.8 0.039∗ 4.4 ± 6.2 3.2 ± 3.8 NS
∗ significant difference, P < 0.05.
showed a significant, positive association with the preva-
lence of vertebral fractures. Diabetes was not associated
with an increased risk of vertebral fractures.
Theprevalenceofnon-vertebralosteoporoticfracturesin
HD patients was 13.5% (26 fractures in total: 12 forearms,
6 hip fractures and 8 at other sites). Among all the differ-
ent variables analysed (general, clinical, biochemical and
therapeutic), only age was positively associated with the
prevalence of peripheral osteoporotic fractures. In fact, the
risk of having peripheral osteoporotic fractures increased
7% per year.
Relationship between vascular calcifications, fragility
fractures and mortality
Vascular calcifications in medium calibre arteries were
statistically significant and positively associated with a
higher rate of prevalent vertebral fractures, but there wasVascular calcification and fractures in haemodialysis 243
Table 4. Relativerisk(OR)ofvertebralfracturesinhaemodialysispatientswith(yes)orwithout(no)vascularcalcificationsindifferentcalibrearteries,
adjusted by age and sex
Vertebral fractures (%) OR (95% CI)
Calcifications in large calibre arteries Yes 26.5 3.8 (0.5–31.6)
No 6.3
Calcifications in medium calibre arteries Yes 30.9 6.5 (1.4–29.8)∗
No 6.5
Calcifications in small calibre arteries Yes 23.8 0.96 (0.3–3.1)
No 23.1
∗significant difference, P < 0.05.
Fig.1. Kaplan–Meieranalysisinwomen(A)withprevalentseverevascu-
larcalcificationsatanyvascularsite,(B)withprevalentvertebralfractures.
no relationship between vascular calcifications and periph-
eral osteoporotic fractures. At other sites such as large cali-
brearteries,therewasatrend,butnostatisticallysignificant
differences (Table 4).
After 2 years of follow-up, 25 women (34.7%), and
39 men (32.2%) died. In men, no significant association
wasobservedbetweenvascularcalcificationsandmortality.
In contrast, 93.3% of women who died had severe vascular
calcifications at least in one of the studied areas. In women
(Figure 1A), severe vascular calcifications were positively
associated with mortality after adjustments by age and time
on HD (Cox multiple regression analyses) [RR = 3.2 (1.0–
10.0),P<0.05].WhenserumiPTH,serumCaandcumula-
tiveintakeofcalcitriolwereincludedascovariates,asimilar
behaviour was observed [RR = 3.8 (1.1–13.6), P < 0.05],
but only severe vascular calcifications were independently
associated with mortality.
As Figure 1B depicts, women with vertebral fractures
showed also a higher mortality rate [RR = 4.8 (1.7–13.4)]
adjusted by age, time on HD and severe vascular calcifi-
cations (Cox multiple regression analysis)]. When serum
iPTH, serum Ca and cumulative intake of calcitriol were
included as covariates, a more marked effect was observed
[RR=6.3(2.0–20.3,P<0.005),butonlytheprevalenceof
vertebral fracture was independently associated with mor-
tality. No differences were found in men. No relationship
between non-vertebral fractures and mortality was found
either in men or in women.
Discussion
In the recent years, the study of vascular calcifications, de-
mographic, clinical and biochemical parameters and bone
fractures in patients with CKD has gained great interest,
mainly due to their great impact on morbidity and mortal-
ity [5,26].
Calcification in the vessel walls occurs at two sites: the
intima and the media. Calcification of the intima is fre-
quently localized in the aorta and coronaries and associated
with atherosclerotic burden. Calcification of the media oc-
curs in the elastic lamina of the large and medium calibre
arteries, it increases with age and it is frequent in CKD and
diabetic patients. The complications of these two types of
vascular calcifications are different; however, they greatly
account for the increase in morbidity and mortality of CKD
patients [27–29].
In this study, prevalent aortic calcifications were signifi-
cantly higher in HD patients (79%) than in a random-based
general population of the same age, sex and region (37.5%)
[25]. Similar results have been reported in other studies
with HD patients [30]. Moreover, women on HD showed
anincreasedriskofhavingsevereaorticcalcificationscom-
pared with women from the general population, probably
due to a combination of atherosclerosis and arteriosclerosis
with intima and media vascular calcifications.
Most of the previous studies have focused their interest
on the aorta and coronary arteries. In this study, however,
we also looked at other sites (digital, palmar arch, radial,
uterine/spermatic, femoral and iliac arteries) and we also
looked at the severity of vascular calcifications using a
semiquantitative method. Another original and important
aspect of the present work was to investigate the relation-
ship between the prevalence of vascular calcifications in
different arterial territories—classified according to their
size and the predominant constituent of tunica media—and
thedifferentvariablesstudied[31–33].Wefoundarelation-
ship between the prevalence of vascular calcifications and
the calibre of the arteries. In HD patients, the prevalence of
vascular calcifications in large calibre arteries was higher
than that in medium and small calibre arteries-–four times
in the latter. These results could be at least partly due to the
different arterial wall structure of the three categories of
arteries studied [34], which may also imply relevant func-
tional changes in the vasculature.
Inaddition,theseverityofvascularcalcificationsinsmall
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women(19.4%versus4.8%,P<0.05),afindingthatcould
be partly related to the protective role of oestrogens in
inflammation, atherosclerosis and calcification, a common
finding in young women but also verifiable even in elderly
women [35–37].
Among demographic, general and clinical parameters,
age was positively associated with vascular calcifications
in large and medium calibre arteries, reinforcing the role
of age as a risk factor for atherosclerosis and arterioscle-
rosis [38]. Time on HD and total time on RRT were pos-
itively associated with vascular calcifications, particularly
in medium calibre arteries, in which each year on RRT in-
creased the risk of having vascular calcifications by ∼15%.
These results are in agreement with previous studies that
have identified the time spent on dialysis as an important
risk factor, mainly for the medial but also for the intima
arterial calcifications [3,4,38,39].
Other meaningful clinical or biochemical variables, such
as hypertension, hyperlipidaemia, hypercalcaemia, hyper-
phosphataemia, hyper- or hypoparathyroidism, corticos-
teroid treatment, cumulative intake of Ca-, calcitriol- and
Al-containing phosphate binders or elevated Ca × P prod-
uct,didnotshowanysignificantassociationwiththepreva-
lence and severity of vascular calcifications.
Interestingly, high serum haemoglobin levels were asso-
ciated with a lower prevalence of severe vascular calcifica-
tionsinlargeandmediumcalibrearteries.Thisfindingisin
agreement with the well-known fact that chronic anaemia
results in an increased cardiac output which, over time,
leads to ventricular dilation, hypertrophy and the arterial
remodelling of central elastic arteries such as the aorta and
the carotids, leading to arterial enlargement, compensatory
arterial intima-media thickening and arteriosclerosis [40].
Diabetes, a highly prevalent condition in HD patients,
was strongly associated with the prevalence of calcifica-
tions, particularly in small calibre arteries. In fact, the risk
of having any type of vascular calcification increased from
18 to 38 times in all the comparisons carried out between
diabeticandnon-diabeticHDpatients.Thisstrong,positive
association has been already reported in diabetic patients
with no CKD [41–43].
So far, few studies on HD patients have focused on the
prevalenceofvertebralfractures[44],clinicalandbiochem-
ical parameters and current treatments. We found that the
prevalence of vertebral fractures (26.5%) was higher than
that documented in previous studies [44–46], but similar to
thatobservedinageneralpopulation(25%)recruitedinthe
same geographical area with similar age and sex patterns to
thoseofthecohortofHDpatientsstudied[24].Onlyageand
time on HD showed a positive and statistically significant
association with a higher prevalence of vertebral fractures.
In agreement with other recently published studies, none
of the biochemical variables or previous treatments showed
any significant association with vertebral fractures [46].
Non-vertebral (peripheral) osteoporotic bone fractures,
particularly hip fractures, seem to be more prevalent in
dialysis patients [47]. In agreement with the DOPPS II
study (2.6%), we observed a 3% prevalence of hip fractures
and a clearly positive association of hip fractures with age
[48]. Although PTH levels might be an independent risk
factor for osteoporotic fractures [12,47], the association of
these two parameters is difficult to prove in cross-sectional
or short-term follow-up studies (2 years), as is the case in
our study. Therefore, similar to us, Stehman-Breen et al.
[49] did not find any association between PTH and hip
fracture in HD patients. In any case, the small number of
hip fractures (n = 6) in our study might be insufficient to
infer a more detailed explanation.
Vascular calcifications, osteoporotic fractures
and mortality
Even though the pathogenetic factors linking vascular cal-
cifications and bone fragility are not clear, several studies
have shown a greater predisposition to develop vascular
calcifications when bone turnover is low [50–52]. In our
study, we have found a positive relationship between os-
teoporotic vertebral fractures and vascular calcifications in
some large and medium calibre arteries, mainly in femoral
anduterine/spermatic,butnotinsmallcalibrearteries.This
finding could be related to the reduced amount of muscle
cells present in small calibre arteries. In fact, only vascu-
lar smooth cells derived from the media from large and
medium-size calibre arteries are those that undergo calci-
fication and bone- and cartilage-like phenotypic changes
under several in vitro experimental conditions [15]. In ad-
dition, the reduced number of patients with calcification in
small calibre arteries makes it difficult to draw definitive
and more solid conclusions in this area.
In agreement with our results, other authors have also
found a relationship between large-size arteries (aorta) and
osteoporotic fractures in the general population [53], rein-
forcing the idea that there is a positive association between
vascular calcifications and osteoporotic fractures in both
the general and HD population.
The Framminghan study, carried out in the general pop-
ulation, has shown that vascular calcifications are indepen-
dent predictors of vascular morbidity and mortality [54].
In our study, only women on HD showed a positive associ-
ation between prevalent severe vascular calcifications and
mortality. Conversely, no association was found in men,
supporting the hypothesis that there are relevant sex differ-
ences in which the arterial remodelling effect of hormones
could be implicated. Cardiovascular risk factors may have
a different impact according to sex; for example, in the
general population, cholesterol is more important for car-
diovascular risk in men than in postmenopausal women, in
whom hypertension, diabetes and its combination play a
major role [55].
Similar to what has been described in the general pop-
ulation [20,56], HD women showed a positive association
between prevalent vertebral fractures and mortality. This
finding, after only 2 years of follow-up, stresses the role
and importance of bone health as an independent parame-
ter related not only to morbidity and quality of life but also
to mortality.
We are aware of some of the limitations of our study.
Firstly, not only the relatively small sample size but also
the only 2 years of follow-up may have prevented us from
obtaining associations among some of the other relevant
variables studied. Secondly, since we used a non-highlyVascular calcification and fractures in haemodialysis 245
sensitive technique such as X-rays to detect vascular cal-
cifications, it is possible that the use of more specific and
sensitive techniques, such as electron beam computed to-
mography (EBCT) or spiral computed tomography [57–
60], might have added additional useful information. How-
ever, in favour of our results, recent studies have shown a
good correlation between EBCT and X-rays [61,62]. In any
case, the fact that we found a positive association with a
medium-sizesample,usingalesssensitivebutwidelyavail-
abletechniqueasthestandardizedX-rays,demonstratesthe
strength of the association between vascular calcifications,
bone fractures and mortality.
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